Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brolucizumab in suboptimal anatomically controlled neovascular AMD
NCT04679935Phase 4Completed
- Sponsor
- Novartis
- Start
- Jul 2021
- Primary completion
- Jan 2024
- Modality
- scFv Fragments, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 4 trial of brolucizumab in neovascular age-related macular degeneration (NVAMD), sponsored by Novartis. Started Jul 2021; status: completed.
02
Drugs
brolucizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT04679935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04679935.